Skip to main content
Clinical Trials/JPRN-UMIN000036424
JPRN-UMIN000036424
Completed
N/A

An observational study to evaluate clinical utility of the pursuit of RAS status using ctDNA analysis to investigate the optimal patient population for anti-EGFR re-challenge therapy - REMARRY Study

ational Cancer Center Hospital East0 sites180 target enrollmentApril 18, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Patients with RAS/BRAF V600E wild-type unresectable advanced or recurrent colorectal cancer who have been treated with anti-EGFR monoclonal antibody
Sponsor
ational Cancer Center Hospital East
Enrollment
180
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 18, 2019
End Date
March 31, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
ational Cancer Center Hospital East

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\)Severe comorbidity. (a)Active multiple cancer (b)Uncontroled central nervous system or leptomeningeal metastasis (c)Mental illness or mental symptoms that would interfere with participation in the study 2\)Any patients who are regarded as inadequate for anti\-EGFR monoclonal antibody re\-challenge by investigators. 3\)Intolerant to previous irinotecan therapy. 4\)Comorbidity or history of severe pulmonary disease. 5\)Men/women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test. 6\)Active HCV or HIV infection. 7\)Any other patients who are regarded as inadequate for study enrollment by investigators.

Outcomes

Primary Outcomes

Not specified

Similar Trials